Zantac (ranitidine) is a drug used to treat and prevent heartburn, stomach ulcers, and other conditions that cause too much acid to build up in the stomach available both by prescription and over the counter. On April 1, 2020, the FDA announced that it had requested manufacturers of ranitidine drugs from the market due to an ongoing investigation of the presence of a certain carcinogen called NDMA—which may potentially cause cancer, even in small amounts.
A new study in December 2020 from the American Chemical Society suggests that the presence of NDMA resulted from the degradation of the active chemical contained in Zantac. This means that the amount of NDMA present in ranitidine increases the longer it is kept on the shelves. The significance of this study shows that Zantac may produce high carcinogen concentrations well in excess of the FDA’s acceptable consumption limit of NDMA.
Ongoing study and increasing data suggest a strong correlation between the active ingredient in Zantac and development of cancer in certain users of the drug. Since NDMA exposure is suspected to increase the risk of certain cancers, you should consult with your doctor if you experience certain symptoms such as weight loss, back pain, yellowing of the skin or eyes, itchy skin, or painful urination.
The Zantac lawsuits have been consolidated into multi-district litigation in the Southern District of Florida. Contact us if you took Zantac or any ranitidine product and have been diagnosed with cancers such as bladder, liver, stomach or pancreatic cancer.